Skip to main content
. 2018 Nov 21;16(11):457. doi: 10.3390/md16110457

Figure 3.

Figure 3

Neuroprotective effects of compounds 1–6 on Neuro2a cells treated with 6-OHDA (50 µM). All compounds were added to the cell suspension 1 h before treatment with 6-OHDA or 1 h after treatment with 6-OHDA. (a) Viability of the 6-OHDA-treated cells incubated with compounds 1 and 1a at 10 µM; (b) Viability of 6-OHDA-treated cells incubated with compounds 2 and 3 at 10 µM; (c) Viability of 6-OHDA-treated cells incubated with compounds 4 and 5 at 10 µM; (d) Viability of the 6-OHDA-treated cells incubated with compound 6 (1 and 10 µM) * Difference between data for compounds and for 6-OHDA was statistically significant with p ≤ 0.05.